These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 26523855

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I, Faubion WA.
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [Abstract] [Full Text] [Related]

  • 8. [Anti-TNF therapy and Crohn's disease].
    Peyrin-Biroulet L.
    Gastroenterol Clin Biol; 2008 May; 32(5 Pt 1):478-81. PubMed ID: 18439777
    [No Abstract] [Full Text] [Related]

  • 9. [Anti-TNF agents, the class of drugs that promotes treatment for Crohn disease].
    Michetti P.
    Rev Med Suisse; 2008 Jan 23; 4(141):187-8. PubMed ID: 18335883
    [No Abstract] [Full Text] [Related]

  • 10. Anti-TNF antibody therapy in Crohn's disease: the risk of a switch.
    Ricart E, Ordás I, Panés J.
    Gut; 2012 Feb 23; 61(2):169-70. PubMed ID: 22068167
    [No Abstract] [Full Text] [Related]

  • 11. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A, Bonnet D, Thebault S, Alric L.
    Gastroenterol Clin Biol; 2010 Sep 23; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract] [Full Text] [Related]

  • 12. Anti-TNF therapy is associated with decreased imaging and radiation exposure in patients with Crohn's disease.
    Patil SA, Rustgi A, Quezada SM, Flasar MH, Vandermeer F, Cross RK.
    Inflamm Bowel Dis; 2013 Jan 23; 19(1):92-8. PubMed ID: 22508292
    [Abstract] [Full Text] [Related]

  • 13. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P, Zwolińska-Wcisło M, Przybylska M, Mach T.
    Przegl Lek; 2011 Jan 23; 68(9):602-5. PubMed ID: 22335009
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD, Richards R.
    Am J Gastroenterol; 2009 Mar 23; 104(3):792-3. PubMed ID: 19262532
    [No Abstract] [Full Text] [Related]

  • 17. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2004 Mar 23; 4 Suppl 3():S25-33. PubMed ID: 15583528
    [Abstract] [Full Text] [Related]

  • 18. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV, Jaganathan S, Bedenbaugh AV, Palmer L, Schwartz DA.
    Curr Med Res Opin; 2014 Sep 23; 30(9):1821-6. PubMed ID: 24884302
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M, Haddad W, Jeddi H, Karoui S, Ben Mustapha N, Kallel L, Fekih M, Matri S, Boubaker J, Filali A.
    Tunis Med; 2012 Feb 23; 90(2):101-7. PubMed ID: 22407620
    [Abstract] [Full Text] [Related]

  • 20. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE, Kamm MA, Hartono JL, Lust M.
    J Gastroenterol Hepatol; 2013 Oct 23; 28(10):1595-9. PubMed ID: 23662928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.